Clinical trials: Adjuvant Drug Therapy
Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
This trial is a Phase II study. All patients are resectable Gastric or Gastroesophageal Junction Adenocarcinoma, Eastern Cooperative Oncology Group (ECOG) performance status 0-1.The purpose of this study is to evaluate the…
- Trial name
- NCT05960955
- Testing
- Cadonilimab, AK117, Oxaliplatin
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Akeso
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer
Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer
Randomized phase III trial to compare the effectiveness of surgery with or without combination chemotherapy in treating patients who have stage I non-small cell lung cancer.
- Conditions
- Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer
- Trial name
- NCT00002852
- Testing
- paclitaxel, carboplatin, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer, Surgery
Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma
The effect of neo-adjuvant immunochemotherapy on survival of patients with thoracic esophageal squamous cell carcinomas remains unknown.
- Conditions
- Esophageal Cancer, Surgery, Neoadjuvant Treatment, Survival
- Trial name
- NCT04280822
- Testing
- Neoadjuvant immunochemotherapy
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Henan Cancer Hospital
Cancer Survivors, Cardiotoxicity
In-Bedroom Renewed Air as Anti-inflammatory Adjuvant Therapy in Cancer Survivors
The BREATHS trial aims to investigate whether overnight in-bedroom air filtration reduces inflammation and cardiac biomarkers in adult survivors of cancer who are at high risk for cardiovascular complications.
- Conditions
- Cancer Survivors, Cardiotoxicity, Cardiovascular Toxicity Induced by Antitumoral Drugs
- Trial name
- BREATHS (NCT06778122)
- Testing
- High efficiency particulate air filtration system (nightly administration), High efficiency particulate air filtration system (nightly and daily administration)
- Where
- 3 sites in Spain
- Volunteers
- 10 people
- Sponsor
- University College, London
Breast Cancer
Tamoxifen in Treating Women With High-Risk Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen.
- Trial name
- NCT00002542
- Testing
- CMF regimen, cyclophosphamide, doxorubicin hydrochloride
- Where
- 48 sites in Canada
- Volunteers
- 672 people
- Sponsor
- NCIC Clinical Trials Group
Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer
ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer
This is a Phase II, multicenter, randomized clinical trial evaluating a ctDNA-guided approach to de-escalate adjuvant chemotherapy in patients with hormone receptor (HR)-positive, HER2-negative early-stage breast cancer.
- Conditions
- Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer, Early-Stage Breast Cancer, HER2-negative Breast Cancer
- Trial name
- DNADalHR (NCT06970912)
- Testing
- Dalpiciclib + Aromatase Inhibitor with ctDNA-Guided Therapy, Taxane-Based Neoadjuvant Chemotherapy
- Where
- China
- Volunteers
- 393 people
- Sponsor
- Peking University People's Hospital
Ileostomy, Rectal Cancer
The Stoma Closure Before or After Adjuvant Therapy Trial
This is an open-label multicenter controlled trial, including 28 centers from the Rete Oncologica (Oncological Network) of Piemonte and Valle d'Aosta in Italy (http://www.reteoncologica.it).
- Trial name
- STOMAD (NCT04372992)
- Testing
- Timing of stoma closure
- Where
- 28 sites in Italy
- Volunteers
- 14 people
- Sponsor
- Ospedale Umberto I di Torino
Gastric Cancer
Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer
The purpose of the study is to evaluate the efficacy and safety of S-1 plus Oxaliplatin versus S-1 only as adjuvant chemotherapy after curative distal gastrectomy in patients with locally advanced gastric cancer.
- Trial name
- RESCUE-GC (NCT02867839)
- Testing
- Oxaliplatin plus S-1, S-1 only
- Where
- 15 sites in China
- Volunteers
- 29 people
- Sponsor
- Peking University Cancer Hospital & Institute
Esophageal Cancer
Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma
Esophageal cancer is a highly aggressive malignancy with a poor overall outcome. Five year survival rate after radical esophagectomy is modest at about 40%.The patients with regional lymph node metastases have worse outcome than…
- Trial name
- NCT02133612
- Testing
- paclitaxel; cisplatin
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Chinese Academy of Medical Sciences
Hepatocellular Carcinoma, Neoplasm Metastasis
Capecitabine to Prevent Recurrence of Hepatocellular Carcinoma After Curative Resection
The purpose of this study is to determine whether capecitabine is effective to prevent disease recurrence after curative hepatic resection in patients with hepatocellular carcinoma.
- Trial name
- NCT00561522
- Testing
- Capecitabine, No other preventive treatment
- Where
- China
- Volunteers
- 290 people
- Sponsor
- Fudan University
Solid Tumors, Adult
PANK-003 Cell Injection Combined with Standard Adjuvant Chemotherapy After Surgery in Patients with Solid Tumors
A single-center, single-arm, dose-escalation exploratory clinical trial on the safety and efficacy of PANK-003 cell injection(Peripheral blood-derived allogeneic natural killer cells )combined with standard adjuvant chemotherapy…
- Trial name
- NCT06897228
- Testing
- PANK-003 cell injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shenzhen Celconta Life Science Co., Ltd.
Non-small Cell Lung Cancer Stage III, Borderline Resectable Carcinoma
Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC
A Phase II, interventional study of neoadjuvant durvalumab (MEDI 4736) and platinum-based Chemotherapy, followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidation durvalumab, in participants…
- Trial name
- ACCESS (NCT06998719)
- Testing
- Durvalumab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Bi Nan
Norovirus
Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine in Children
The purpose of this study is to select the optimal formulation of the norovirus vaccine from different concentrations of virus-like particles (VLP) combined with aluminum hydroxide for further development in children.
- Trial name
- NCT02153112
- Testing
- GI.1/GII.4 (15/15), GI.1/GII.4 (15/50), GI.1/GII.4 (50/50)
- Where
- 12 sites in Colombia, Finland and 1 more
- Volunteers
- 840 people, healthy volunteers welcome
- Sponsor
- Takeda
Non-small Cell Lung Cancer
Adjuvant CCRT vs CT in Minimal N2 NSCLC
This study propose adjuvant concurrent chemoradiotherapy vs chemotherapy alone in completely resected microscopic N2 NSCLC
- Trial name
- NCT01066234
- Testing
- concurrent chemoradiotherapy, chemotherapy only
- Where
- South Korea
- Volunteers
- 17 people
- Sponsor
- Samsung Medical Center
Breast Cancer, Chemotherapy, Adjuvant
Adjuvant FEC Versus EP in Breast Cancer (MIG5)
In this multicenter, randomized phase III trial, node positive early breast cancer patients are randomly assigned to receive either 6 cycles of FEC (5-fluorouracil 600 mg/m2, epirubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, on…
- Trial name
- MIG5 (NCT02450058)
- Testing
- 5-fluorouracil, epirubicin, cyclophosphamide
- Where
- 8 sites in Italy
- Volunteers
- 1,055 people
- Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Breast Cancer
Studying the Benefits of Adjuvant Sequential vs. Combined Taxane Based Chemotherapy, Followed by Different Biological Treatment Strategies in Early, HER2-positive Breast Cancer
This is an open-label, multicenter randomized controlled, Phase III study comparing the disease free survival after randomisation in patients treated with 3 cycles of Epirubicin-Fluorouracil-Cyclophosphamide (FEC)-chemotherapy…
- Trial name
- NCT00670878
- Testing
- 3 x FEC 3 x DOC / Gemcitabine, 3 x FEC 3 x DOC
- Where
- Germany
- Volunteers
- 799 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Breast Neoplasms
The Synergism Or Long Duration (SOLD) Study
The purpose of the study is to compare disease-free survival (DFS) of women treated with concomitant trastuzumab plus docetaxel followed by FEC to that of the women treated with the same regimen followed by single-agent…
- Trial name
- SOLD (NCT00593697)
- Testing
- trastuzumab (9 weeks) + docetaxel, trastuzumab (9 weeks) + docetaxel + CEF + trastuzumab (up to 51 weeks)
- Where
- Finland
- Volunteers
- 2,168 people
- Sponsor
- Finnish Breast Cancer Group
Stomach Neoplasm, GastroEsophageal Cancer
PREACT Study: Locally Advanced Gastric Cancer, Chemoradiotherapy vs. Chemotherapy Followed by D2 Surgery and Adjuvant Chemotherapy
Although the incidence of gastric cancer has been substantially declining for several decades, it is still the sixth most common cancer and the fourth most frequent cause of cancer death worldwide.
- Conditions
- Stomach Neoplasm, GastroEsophageal Cancer, Adenocarcinoma, Locally Advanced Cancer
- Trial name
- PREACT (NCT03013010)
- Testing
- Tegafur-Gimeracil-Oteracil Potassium, Chemoradiotherapy, Gastric resection
- Where
- China
- Volunteers
- 204 people
- Sponsor
- Shanghai Cancer Hospital, China
Colorectal Cancer, Liver Metastases
Living Donor Liver Transplantation for Unresectable Colorectal Cancer Liver Metastases
Patients with unresectable liver metastases (LM) from colorectal cancer (CRC)have a poor prognosis. In patients with resectable disease, surgery offers a distinct survival benefit.
- Trial name
- NCT02864485
- Testing
- live donor liver transplantation
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Colorectal Cancer, Colorectal Liver Metastases
Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI
Eligible patients are patients with contraindication to preoperative oxaliplatin based-chemotherapy who underwent resection of no more than 10 colorectal liver metastases after preoperative FOLFIRI based chemotherapy with or…
- Trial name
- IRIMAD (NCT06501482)
- Testing
- Postoperative reintroduction of FOLFIRI based chemotherapy
- Where
- France
- Volunteers
- 254 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris